Skip to content

Effect and Safety of Active Circle of Breath Technology in Bronchiectasis: a Randomized Control Trial

Effect and Safety of Active Circle of Breath Technology in Bronchiectasis: a Randomized Control Trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100046143
Enrollment
Unknown
Registered
2021-05-05
Start date
2021-05-01
Completion date
Unknown
Last updated
2021-12-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bronchiectasis

Interventions

Control group:Muscle stretching of the thorax

Sponsors

The Second Xiangya Hospital of Central South University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Aged from 18 to 75 years and clinical diagnosis of bronchiectasis; 2. Patients with bronchiectasis were in stable stage (there was no significant change in respiratory symptoms during the day and night for 4 consecutive weeks, and no acute exacerbation of bronchiectasis or acute upper respiratory tract infection occurred within 4 weeks); 3. More than one pulmonary exacerbation of bronchiectasis occurred in two years; 4. Daily sputum volume in the previous year was >= 10 ml; 5. Patients had not received airway clearance or rehabilitation treatment in the past; 6. Patients are able to receive treatment follow-up and have a certain reading ability.

Exclusion criteria

Exclusion criteria: 1. Cystic fibrosis; 2. Currently smoking or smoking index >= 10 pack-years or HRCT showing emphysema; 3. Previous diagnosis of asthma; 4. Active pulmonary tuberculosis; 5. Any contraindications for airway clearance: pneumothorax, intracranial hypertension, recent history of eye surgery, hemoptysis; 6. Participation in other clinical trials within 3 months before screening; 7. Withdrawal of the informed consent.

Design outcomes

Primary

MeasureTime frame
Sputum volume during the first intervention and 24 hours later;Quality of Life-Bronchiectasis Respiratory Symptoms scores (QOL-B-RSS);

Secondary

MeasureTime frame
Sputum volume during the last intervention and 24 hours later;Number of exacerbations ;Time to exacerbation;Lung function;mMRC scale;6-min walk test;Leicester Cough Questionnaire (LCQ);Bronchiectasis Health Questionnaire (BHQ) score;Hospital Anxiety and Depression Scale (HADS) score;Sputum color and microbiology evaluation;Systemic inflammation biomarkers;Treatment adherence;

Countries

China

Contacts

Public ContactLuo Hong

The Second Xiangya Hospital of Central South University

drluohong@csu.edu.cn+86 731 85296204

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026